Isomangiferin, a Novel Potent Vascular Endothelial Growth Factor Receptor 2 Kinase Inhibitor, Suppresses Breast Cancer Growth, Metastasis and Angiogenesis.

about

Isomangiferin, a Novel Potent Vascular Endothelial Growth Factor Receptor 2 Kinase Inhibitor, Suppresses Breast Cancer Growth, Metastasis and Angiogenesis.

Item

http://www.wikidata.org/entity/Q52599657

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Isomangiferin, a Novel Potent ...... , Metastasis and Angiogenesis.

@en

Isomangiferin, a Novel Potent ...... , Metastasis and Angiogenesis.

@nl

type

Item

label

Isomangiferin, a Novel Potent ...... , Metastasis and Angiogenesis.

@en

Isomangiferin, a Novel Potent ...... , Metastasis and Angiogenesis.

@nl

prefLabel

Isomangiferin, a Novel Potent ...... , Metastasis and Angiogenesis.

@en

Isomangiferin, a Novel Potent ...... , Metastasis and Angiogenesis.

@nl

P1476

Isomangiferin, a Novel Potent ...... h, Metastasis and Angiogenesis

@en

P2093

Banghua Wang

http://www.w3.org/2001/XMLSchema#string

Jianxia Liu

http://www.w3.org/2001/XMLSchema#string

Meichun Hu

http://www.w3.org/2001/XMLSchema#string

Zexia Wang

http://www.w3.org/2001/XMLSchema#string

Zhifeng Ning

http://www.w3.org/2001/XMLSchema#string

P2860

The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer

Targeting vascular endothelial growth factor receptor 2 and protein kinase D1 related pathways by a multiple kinase inhibitor in angiogenesis and inflammation related processes in vitro

Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.

Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function.

Hydrophilic molybdenum oxide nanomaterials with controlled morphology and strong plasmonic absorption for photothermal ablation of cancer cells.

Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.

Mangiferin inhibits tumor necrosis factor-α-induced matrix metalloproteinase-9 expression and cellular invasion by suppressing nuclear factor-κB activity.

An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)

Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo

VEGFR2-Targeted Three-Dimensional Ultrasound Imaging Can Predict Responses to Antiangiogenic Therapy in Preclinical Models of Colon Cancer.

P304

11-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4048/JBC.2018.21.1.11

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jia Shen

P577

2018-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29628979

http://www.w3.org/2001/XMLSchema#string

P932

5880961

http://www.w3.org/2001/XMLSchema#string